



Half year update on the DBV Technologies liquidity agreement

Bagneux, France, January 14, 2015 – Under the liquidity agreement signed between DBV TECHNOLOGIES and NATIXIS, the following resources were listed in the liquidity account on December 31st, 2014:

8 054 DBV TECHNOLOGIES' shares
1,111,227.16 €

As a reminder, during the last half year liquidity agreement on June 30th, 2014, the following assets appeared on the liquidity account:

9,018 DBV TECHNOLOGIES' shares
478,300.41 €

Under the terms of the liquidity contract, pursuant to Article 12, it is recalled that the following resources have been added as of December 15, 2014:

- EUR 600,000.00

It is specified that at the implementation of the said contract the following resources were listed in the liquidity account:

- 0 titres DBV TECHNOLOGIES shares
- EUR 300,000.00

About DBV Technologies

DBV Technologies is developing Viaskin[®], an innovative new approach to the treatment of allergies – a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin[®] Peanut and Viaskin[®] Milk. The clinical development program for Viaskin[®] Peanut has received Fast Track designation from the US Food and Drug Administration.

DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT).



DBV Technologies Contacts

David Schilansky

Chief Operating Officer

Tel. : +33(0)1 55 42 78 75

david.schilansky@dbv-technologies.com

Susanna Mesa

VP Finance, US Investor Relations & Strategy

Tel. : +1 917-346-3447

susanna.mesa@dbv-technologies.com

Nathalie Donne

Director, Corporate Communication & Business Development

Tel. : +33(0)1 55 42 78 72

nathalie.donne@dbv-technologies.com

DBV IR and Media Contacts

Todd James

U.S. Investor Relations

The Trout Group

Tel. : +1 646-378-2926

tjames@troutgroup.com

Marion Janic

US Media Relations

Rooney & Associates

Tel. : +1-212-223-4017

mjanic@rooneyco.com